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ABSTRACT 
 
Rationale: Coronary artery disease (CAD) is a complex phenotype driven by genetic and environmental 
factors. 97 genetic risk loci have been identified so far, but the identification of additional susceptibility 
loci might be important to enhance our understanding of the genetic architecture of CAD.  
 
Objective: To expand the number of genome-wide significant loci, catalog functional insights, and enhance 
our understanding of the genetic architecture of CAD. 
  
Methods and Results: We performed a genome-wide association study (GWAS) in 34,541 CAD cases and 
261,984 controls of UK biobank Resource followed by replication in 88,192 cases and 162,544 controls 
from CARDIoGRAMplusC4D. We identified 75 loci that replicated and were genome-wide significant 
(P<5x10-8) in meta-analysis, 13 of which had not been reported previously. Next, to further identify novel 
loci we identified all promising (P<0.0001) loci in the CARDIoGRAMplusC4D data and performed 
reciprocal replication and meta-analyses with UK biobank. This led to the identification of 21 additional 
novel loci reaching genome-wide significance (P<5x10-8) in meta-analysis. Finally, we performed a 
genome wide meta-analysis of all available data revealing 30 additional novel loci (P<5x10-8) without 
further replication. The increase in sample size by UK Biobank raised the number of reconstituted gene-
sets from 4.2% to 13.9% of all gene-sets to be involved in CAD. For the 64 novel loci, 155 candidate causal 
genes were prioritized, many without an obvious connection to CAD. Fine-mapping of the 161 CAD loci 
generated lists of credible sets of single causal variants and genes for functional follow-up. Genetic risk 
variants of CAD were linked to development of atrial fibrillation, heart failure and death.  
 
Conclusions: We identified 64 novel genetic risk loci for CAD and performed fine-mapping of all 161 risk 
loci to obtain a credible set of causal variants. The large expansion of reconstituted gene-sets argues in 
favor of an expanded “omnigenic model” view on the genetic architecture of CAD.  
 
Keywords: 
Coronary artery disease, genetics, fine-mapping, genome wide association study, computational biology. 
 
Nonstandard Abbreviations and Acronyms: 
 
1000Genomes   a deep catalog of variation in the human genome based on DNA  
sequencing 
CAD    coronary artery disease 
CARDIoGRAM  the Coronary Artery Disease Genome-wide Replication and  
DEPICT   Data-driven Expression-Prioritized Integration for Complex  
eQTL    expression quantitative trait locus 
GTEx    The Genotype-Tissue Expression 
GWAS    genome-wide association study 
IPA    Ingenuity pathway analysis 
LD    linkage disequilibrium 
meQTL   methylation quantitative trait locus 
SNP    Single-nucleotide polymorphism 
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INTRODUCTION 
 
Coronary artery disease (CAD) is the predominant cause of ischemic heart disease often leading to 
myocardial infarction and a leading cause of death. Globally, deaths due to ischemic heart disease increased 
by 16.6% from 2005 to 2015 to 8.9 million deaths. However, the age-standardized mortality rates are 
decreasing (fell by 12.8%)1 due to preventive and treatment strategies established on evolving knowledge 
of the underlying pathophysiology of CAD.  
 
CAD is a complex disease, resulting from numerous additive and interacting contributions in an 
individual’s environment and lifestyle in combination with their underlying genetic architecture. Since the 
first genome wide association studies for CAD in 20072–4, multiple additional studies with progressively 
larger sample sizes identified 97 genome-wide significant genetic loci associated with CAD5–10 at the time 
of analysis. The continuous effort to identify additional loci associated with CAD and share these early with 
the scientific community is important, especially to enhance our understanding of the biological 
underpinnings of CAD and to catalyze the development of drugs. A comprehensive understanding of the 
genetic architecture of CAD is also essential to enable precision medicine approaches by identifying 
subgroups of patients at increased risk of CAD or its complications and might identify those with a specific 
driving pathophysiology in whom a particular therapeutic or preventive approach would be most useful11. 
 
To further our knowledge of the genetic architecture of CAD, we performed a de novo genome-
wide association study (GWAS) of the UK Biobank Resource and meta-analyses with 
CARDIoGRAMplusC4D data. Our approach led to the identification of 64 novel loci associated with CAD, 
expanding the grand total to 161. These loci were interrogated using bioinformatic approaches to catalog 
and interpret the potential biological relevance of our findings. We also performed network and gene-set 
analyses and propose the omnigenic model to explain our findings. This expanding resource is now 





The data that support the findings of this study are available from the corresponding author upon reasonable 
request. The de novo GWAS analysis and meta-analysis have been posted on Mendeley 
(doi:10.17632/2zdd47c94h.1; doi:10.17632/gbbsrpx6bs.1). A summary of the methods is provided below, 
and a more detailed description of the experimental procedures is provided in the Online Data Supplement. 
 
Study design and samples. 
The study design consisted of a reciprocal two-stage sequential discovery and replication approach (Online 
Figure I) providing the most robust statistical evidence followed by an overall meta-analysis of all available 
data for which currently no replication data were available in this study. First, using the UK Biobank 
Resource we conducted a GWAS to discover SNPs associated with CAD. In stage 2, we took forward all 
promising SNPs reaching nominal significance (P<0.0001) for replication in CARDIoGRAMplusC4D 
data. Replicating SNPs (P<0.05 after Bonferroni adjustment) were meta-analyzed and considered true when 
surpassing the genome-wide significance threshold (P<5×10-8). The reciprocal stage 1 entailed the 
identification for all promising SNPs (P<0.0001) in CARDIoGRAMplusC4D and replication in UK 
Biobank (P<0.05 after Bonferroni adjustment) followed by meta-analysis. Again, SNPs replicating and 
surpassing the genome-wide significance threshold were considered true. A sentinel SNP in a locus was 
defined as the most significant variant in a 1MB region that was independent from other sentinel SNPs 
(r2<0.1). A locus was defined as a region of 1MB at either side of the sentinel SNP. A locus was considered 
novel if the sentinel SNP was not within a 1MB window (at either side) of earlier reported genome-wide 
significant SNPs (Online Table I). Finally, we performed a genome-wide meta-analysis of the UK Biobank 
Resource and CARDIoGRAMplusC4D to identify additional CAD associated loci (P<5×10-8 in meta-
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analysis). A potential sample overlap between the UK Biobank and cohorts of CARDIoGRAMplusC4D 
was estimated to be smaller than 0.1%, no evidence was found that this biased the test-statistics (Online 
Data Supplement). 
 
Candidate genes and insights in biology. 
Candidate causal genes at each of the loci were prioritized based on proximity, eQTL data, Data-driven 
expression-prioritized integration for complex traits (DEPICT)12 analyses and long-range chromatin 
interactions of variants with gene-promoters (see Online Data Supplement).8,13 Summary information of 
genes was obtained via queries in GeneCards, EntrezGene, UniProt, and Tocris. The Mouse Genomic 
Informatic (MGI) database was used for obtaining insights into mammalian phenotypes associated with 
disruption of candidate genes. DEPICT was also used to test for enrichment of gene sets and identify 
relevant tissues and cell types. Ingenuity Pathway Analysis (IPA, June 2017 release) was performed to 
strengthen the biological relevancy of the novel loci.  
 
Insights in loci by associations with other phenotypes. 
The GWAS catalog was queried and a phenome-scan was carried out by intersecting the identified loci with 
the GWAS-catalog and by testing the association of the newly identified SNPs with a wide range of 
phenotypes using linear or logistic regression analysis in UK Biobank (see Online Data Supplement). 
Genetic risk scores (GRS) were constructed using effect estimates obtained CARDIoGRAMplusC4D data 
as described previously.8 Multivariable Cox proportional hazards models were fitted for quintiles of the 
GRS in the UK Biobank Resource, to assess the extent to which the GRS could predict new onset atrial 
fibrillation/flutter and heart failure.  
 
Regulatory DNA and fine-mapping of probable causal variants. 
To systematically characterize the functional, cellular and regulatory contribution of genetic variation we 
employed GARFIELD14, analyzing the enrichment of genome-wide association summary statistics in tissue 
specific functional elements at given significance thresholds. Probabilistic Annotation INtegraTOR 
(PAINTOR) was used to fine-map loci by integrating genetic association signal strength with genomic 
functional annotation data15. We explored the potential target genes of these candidate causal variants by 
determining their direct effects on protein function (missense variants) and evidence connecting the causal 
variant in a Utr-3’ region to gene expression (eQTL) or physical interactions (Hi-C) with the promotor of 
an eQTL gene. Determination of potential causal mechanisms of the potential causal variants based on a) 
missense variation, b) chromatin-interaction between the causal variant and the promotor of a gene for 
which the causal variant was also significantly associated with gene-expression by eQTL analyses, or c) 
Utr3’ overlapping variants that were also significantly associated with gene expression of the same gene 
corresponding to the Utr3’ position. In addition, for genes/mechanisms to be prioritized by eQTL analyses 






Genome wide analyses of 34,541 cases and 261,984 controls. 
 
The stage 1 GWAS analysis in UK biobank (34,541 cases and 261,984 controls, Online Table II) 
of 7,947,838 SNPs revealed 630 suggestive SNPs (P<0.0001) in 442 loci (Online Table III). 86 independent 
SNPs in 75 loci both replicated (P<0.05 Bonferroni adjusted) in stage 2 in up to 88,192 cases and 162,544 
controls of CARDIoGRAMplusC4D, and achieved genome wide significance (P<5×10-8) with no evidence 
of heterogeneity of effects (Phet ≥0.10). 13 of the 75 loci are not established CAD associated loci (Table 1). 
 
 










Table 1. 64 novel genome-wide significant CAD loci. 
 
Cytoband Position Lead SNP A1 A2 Freq Variant function Candidate Genes Resource OR (95%CI) P-value 
1p36.33 2252205 rs36096196 T C 0.15 downstream MORN1%,SKI# MA 1.05(1.03-1.06) 1.3x10-8 
1p36.32 3325912 rs2493298 A C 0.14 intronic PRDM16%*#,PEX10^,PLCH2^,RER1^ UK 1.06 (1.04-1.08) 1.9x10-9 
1p34.3 38461319 rs61776719 A C 0.53 intergenic FHL3%$#, UTP11$, SF3A3$, MANEAL$, INPP5B$ UK 1.04 (1.03-1.06) 1.1x10-9 
1p13.2 115753482 rs11806316 A G 0.37 intergenic NGF%^#, CASQ2^ CA 0.96 (0.95-0.97) 4.9x10-10 
1q32.2 210468999 rs60154123 T C 0.15 intergenic HHAT%$,SERTAD4#^,DIEXF^ MA 1.05(1.03-1.06) 2.5x10-8 
1q42.2 230845794 rs699 A G 0.58 missense AGT%*$, CAPN9^, GNPAT^ CA 0.96 (0.95-0.98) 2.1x10-8 
2p21 45896437 rs582384 A C 0.53 intronic PRKCE%,TMEM247^ MA 1.03(1.02-1.05) 7.6x10-9 
2q24.3 164957251 rs12999907 A G 0.82 intergenic FIGN% UK 1.06 (1.04-1.07) 2.4x10-11 
2q32.1 188196469 rs840616 T C 0.35 intergenic CALCRL%$#^, TFPI$# CA 0.96 (0.95-0.97) 3.0x10-9 
2q37.3 238223955 rs11677932 A G 0.32 intergenic COL6A3%#^ MA 0.97(0.96-0.98) 2.6x10-8 
3p21.31 46688562 rs7633770 A G 0.41 intergenic ALS2CL%$#,RTP3^ MA 1.03(1.02-1.04) 1.1x10-8 
3p21.31 48193515 rs7617773 T C 0.67 intergenic CDC25A%, SPINK8$, MAP4$,ZNF589$ UK 1.04 (1.03-1.05) 2.3x10-11 
3q22.1 132257961 rs10512861 T G 0.14 downstream DNAJC13%#, NPHP3#, ACAD11^, UBA5^ CA 0.96 (0.94-0.97) 1.5x10-8 
3q22.3 136069472 rs667920 T G 0.78 intronic STAG1%#^,MSL2#,NCK1#,PPP2R3A# MA 1.05(1.04-1.06) 6.0x10-15 
3q25.31 156852592 rs4266144 C G 0.68 intergenic CCNL1%,TIPARP$^ MA 0.97(0.95-0.98) 1.4x10-8 
3q26.31 172115902 rs12897 A G 0.59 UTR3 FNDC3B%$# CA 0.96 (0.95-0.97) 1.9x10-10 
4p16.3 3449652 rs16844401 A G 0.07 missense HGFAC%*#, RGS12%, MSANTD1^ CA 1.07 (1.04-1.10) 4.0x10-8 
4q21.1 77416627 rs12500824 A G 0.36 intronic SHROOM3%$#^, SEPT11^, FAM47E^,STBD1^ UK 1.04 (1.03-1.05) 4.1x10-10 
4q21.22 82587050 rs11099493 A G 0.69 intergenic HNRNPD%, RASGEF1B# UK 1.04 (1.03-1.06) 5.1x10-10 
4q22.3 96117371 rs3775058 A T 0.23 intronic UNC5C%# MA 1.04(1.03-1.05) 7.6x10-9 
4q32.3 169687725 rs7696431 T G 0.51 intronic PALLD%#^, DDX60L^ UK 1.04 (1.02-1.05) 2.7x10-8 
5p15.31 9556694 rs1508798 T C 0.81 intergenic SEMA5A%$#, TAS2R1^ CA 1.05 (1.04-1.07) 4.8x10-13 
5q11.2 55860781 rs3936511 A G 0.82 intronic MAP3K1%#^,MIER3# MA 0.96(0.95-0.98) 3.7x10-8 
6p25.3 1617143 rs9501744 T C 0.13 intergenic FOXC1% CA 0.95 (0.93-0.96) 2.2x10-8 
6p21.2 36638636 rs1321309 A G 0.49 intergenic CDKN1A%$#,PI16# MA 1.03(1.02-1.04) 3.4x10-8 
6p21.1 43758873 rs6905288 A G 0.57 intergenic VEGFA%#,MRPL14^,TMEM63B^ UK 1.05 (1.03-1.06) 1.9x10-12 
6p11.2 57160572 rs9367716 T G 0.32 intergenic PRIM2%, RAB23$, DST^, BEND6^ CA 0.96 (0.95-0.97) 9.6x10-10 
6q14.1 82612271 rs4613862 A C 0.53 intergenic FAM46A%#^ MA 1.03(1.02-1.04) 6.5x10-10 
6q22.32 126717064 rs1591805 A G 0.49 intergenic CENPW%$ UK 1.04 (1.03-1.06) 2.1x10-10 
6q25.1 150997401 rs17080091 T C 0.08 intronic PLEKHG1%#,IYD^ MA 0.95(0.93-0.96) 6.0x10-9 
7p22.3 1937261 rs10267593 A G 0.20 intronic MAD1L1%$ MA 0.96(0.95-0.98) 1.8x10-8 
7p22.1 6486067 rs7797644 T C 0.23 intronic DAGLB%*$,RAC1$#^,FAM220A$,KDELR2# MA 0.96(0.95-0.98) 2.1x10-8 
7p21.3 12261911 rs11509880 A G 0.36 intronic TMEM106B%$, THSD7A^ CA 1.04 (1.02-1.05) 2.8x10-8 
7p13 45077978 rs2107732 A G 0.09 missense CCM2%*$,MYO1G^ MA 0.94(0.93-0.96) 3.6x10-8 
7q31.2 117332914 rs975722 A G 0.60 intergenic CTTNBP2%,CFTR#,ASZ1^ MA 0.97(0.96-0.98) 4.1x10-8 
8p22 18286997 rs6997340 T C 0.31 intergenic NAT2%^ CA 1.04 (1.02-1.05) 4.9x10-9 
8p21.3 22033615 rs6984210 C G 0.94 intronic BMP1
%$#, SFTPC#, DMTN$,PHYHIP$,DOK2^, 
XPO7^ UK 0.92 (0.90-0.94) 2.1x10-11 
8q23.1 106565414 rs10093110 A G 0.42 intronic ZFPM2%#^ MA 0.97(0.96-0.98) 1.8x10-8 
9q31.2 110517794 rs944172 T C 0.72 intergenic KLF4%# UK 0.96 (0.95-0.97) 1.1x10-11 
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9q33.2 124420173 rs885150 T C 0.73 intronic DAB2IP%$#^ MA 0.97(0.95-0.98) 7.8x10-10 
10p13 12303813 rs61848342 T C 0.64 intergenic CDC123%,NUDT5$,OPTN^ MA 0.96(0.95-0.98) 6.3x10-10 
10q23.1 82251514 rs17680741 T C 0.72 intronic TSPAN14%$#, MAT1A#,FAM213A^ UK 1.05 (1.03-1.06) 2.3x10-11 
10q24.33 105693644 rs4918072 A G 0.27 intergenic STN1%$, SH3PXD2A# UK 1.04 (1.03-1.06) 2.6x10-9 
10q26.13 124237612 rs4752700 A G 0.55 intronic HTRA1%#,PLEKHA1^# MA 0.97(0.96-0.98) 8.0x10-11 
11p15.4 5701074 rs11601507 A C 0.07 missense TRIM5%*, TRIM22%, TRIM6^, OR52N1^, OR52B6^ UK 1.09 (1.06-1.11) 2.1x10-12 
11p11.2 43696917 rs7116641 T G 0.69 intergenic HSD17B12% MA 0.97(0.96-0.98) 1.0x10-8 
11q22.1 100624599 rs7947761 A G 0.72 intronic ARHGAP42%# CA 0.96 (0.95-0.97) 3.0x10-9 
12p13.31 7175872 rs11838267 T C 0.87 intronic C1S%*# MA 1.05(1.04-1.07) 6.1x10-10 
12q22 95355541 rs7306455 A G 0.10 intergenic NDUFA12%, FGD6# CA 0.95 (0.93-0.96) 1.0x10-8 
13q13.1 33058333 rs9591012 A G 0.34 intronic N4BP2L2$^,PDS5B$# CA 0.96 (0.94-0.97) 7.0x10-11 
13q34 113631780 rs1317507 A C 0.26 intronic MCF2L%$, PCID2^, CUL4A^ CA 1.04 (1.03-1.06) 8.4x10-12 
14q23.1 58794001 rs2145598 A G 0.58 intronic ARID4A%$#,PSMA3^ MA 0.97(0.96-0.98) 4.2x10-8 
14q32.13 94838142 rs112635299 T G 0.02 intergenic SERPINA2%#,SERPINA1%* MA 0.87(0.84-0.91) 8.4x10-10 
15q26.2 96146414 rs17581137 A C 0.75 intergenic MA 1.04(1.02-1.05) 1.2x10-8 
16q23.3 81906423 rs7199941 A G 0.40 intronic PLCG2%#^, CENPN$ CA 1.04 (1.03-1.05) 9.2x10-13 
17q11.2 27941886 rs13723 A G 0.51 UTR3 CORO6
%$, ANKRD13B%$, GIT1$, SSH2#$^, 
EFCAB5^ CA 0.96 (0.95-0.97) 5.6x10-10 
17q11.2 30033514 rs76954792 T C 0.22 intergenic COPRS%$,RAB11FIP4^ MA 1.04(1.03-1.05) 1.1x10-8 
17q21.2 40257163 rs2074158 T C 0.82 missense DHX58
%*$, KAT2A%#,RAB5C$#, NKIRAS2^, 
DNAJC7^, KCNH4^, HCRT^, GHDC^ CA 0.95 (0.93-0.96) 2.2x10-10 
18q21.1 47229717 rs9964304 A C 0.72 intergenic ACAA2%#,RPL17^ MA 0.96(0.95-0.97) 1.1x10-9 
19p13.11 17855763 rs73015714 C G 0.80 intergenic MAP1S%#, FCHO1%$, COLGALT1^ CA 0.94 (0.93-0.96) 8.3x10-14 
20q12 39924279 rs6102343 A G 0.25 intronic ZHX3%,PLCG1$#^,TOP1#^ MA 1.04(1.02-1.05) 1.1x10-8 
20q13.12 44586023 rs3827066 T C 0.14 intronic PCIF1%#,ZNF335%#,NEURL2$,PLTP$# MA 1.04(1.03-1.06) 4.4x10-9 
20q13.32 57714025 rs260020 T C 0.13 intergenic ZNF831% MA 1.05(1.04-1.07) 7.9x10-10 
21q21.3 30533076 rs2832227 A G 0.82 intronic MAP3K7CL%$,BACH1# UK 0.96 (0.94-0.97) 1.7x10-9 
 
List of novel CAD associated replicating (P<0.05 Bonferroni adjusted, direction of effect consistent) and surpassing the genome-wide significance 
threshold in meta-analysis of UK Biobank and CARDIoGRAMplusC4D. Full details are shown in Online Tables I, III-XII. Results are shown for 
the discovery, replication, and combined meta-analysis. OR; odds ratio. Resource; UK; UK Biobank as discovery and CARDIoGRAMplusC4D as 
replication, CA; CARDIoGRAMplusC4D as discovery and UK biobank as replication, MA; Genome wide significant in the GWAS meta-analysis. 
% nearest; * coding variants; $ eQTL; # Depict; ^ Hi-C. 
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Next, we re-analyzed the data from the MetaboChip meta-analysis of CARDIoGRAMplusC4D9, 
the CARDIoGRAMplusC4D 1000 genomes meta-analysis7, and the CARDIoGRAM Exome array data16 
to identify the promising SNPs (P<0.0001). We identified 568 promising SNPs located in 375 loci (Online 
Table IV). 113 independent SNPs in 96 loci both replicated (P<0.05 Bonferroni adjusted) in stage 2, UK 
biobank, and achieved genome wide significance in meta-analysis (P<5×10-8), including 21 additional 
novel loci (Table 1 and Online Table V).  
 
Finally, we performed a meta-analysis of CARDIoGRAMplusC4D9, the CARDIoGRAMplusC4D 
1000 genomes meta-analysis7 with UK biobank and identified 30 additional loci for which no replication 
test was available (Table 1, Online Table VI) increasing the total number of genome wide significant CAD 
loci to 161 (Online Figure II). The novel variants were common (>5%, except for 1, rs112635299 near 
SERPINA1). Online Figure III shows the regional associations plot of each novel locus. For some variants, 
a dominant or recessive linkage model appears to be a better fit compared to an additive model (Online 
Table VII). Complete summary statistics of all SNPs in UK Biobank and the UK Biobank- 
CARDIoGRAMplusC4D meta-analysis are available as download on www.cardiomics.net.  
 
Candidate genes and deeper insights into biology. 
 
To disentangle whether associations were driven more by acute myocardial infarction as opposed 
to stable CAD we performed multinomial logistic regression analyses for all genome wide significant 
(P<5×10-8) loci in UK Biobank. 16,875 individuals were only diagnosed with CAD and 17,666 also with 
myocardial infarction. None of the novel loci and only two previously identified variant (rs9349379, 
rs10947789) appear to be mainly driven by its association with myocardial infarction rather than stable 
CAD (FDR P<0.05; Online Table VIII).  
 
We further explored the potential biology of the 64 novel CAD associated loci by prioritizing 155 
candidate causal genes in these loci: 69 genes were in proximity (the nearest gene and any additional gene 
within 10kb) of the lead variant, 9 genes contained coding genetic variation in LD (r2>0.8) with the lead 
variant (Online Table IX), 50 genes were selected based on expression quantitative trait loci (eQTL) 
analyses (Online Table X), 64 genes showed significant chromatin-interactions (Hi-C) between the genetic 
variant and promoter of the gene (Online Table XI), and 60 genes were prioritized based on DEPICT 
analyses (Online Table XII). Of the 155 candidate genes, 63 were prioritized by multiple methods of 
identification, which may be used to prioritize candidate causal genes. A summary of the current function 
annotation of each novel candidate gene is provided in Online Table XIII and knowledge on pharmacologic 
compounds and nutrients influencing these genes is provided in Online Table XIV. Next, we performed a 
systematic search in the Mouse Genome Informatics (MGI) database to identify the effect of mutations in 
orthologous genes for these candidate causal genes (details in Online Table XV). In brief, we identified 34 
genes that expressed at least one cardiovascular system phenotype (AGT, ARHGAP42, BACH1, CALCRL, 
CASQ2, CCM2, CDC123, CDKN1A, FIGN, FOXC1, GIT1, GNPAT, HCRT, HSD17B12, MAP1S, 
MAP3K1, MSANTD1, NGF, NPHP3, PCIF1, PDS5B, PLCG1, PLEKHA1, PPP2R3A, PRDM16, PRKCE, 
RAC1, SEMA5A, SH3PXD2A, TFPI, TIPARP, TMEM106B, VEGFA, ZFPM2) and 34 genes that affected 
other potentially plausible traits linked to CAD, including metabolic/lipid/adipose/weight abnormalities 
(AGT, CORO6, FIGN, GIT1, KAT2A, NGF, PPP2R3A, NPHH3, SH3PXD2A, TMEM106B, VEGFA, ZHX3, 
OPTN, FAM213A, DNAJC7, COPRS), abnormalities in inflammation or white blood cells (DHX58, FHL3, 
HNRNPD, PLCG2, PRDM16, TFPI, VEGFA, ZNF335, PRKCE, MYO1G, RAC1, ARID4A), and 
abnormalities in platelets or coagulation (FHL3, PLCG2, TFPI, VEGFA, DST, KLF4).  
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Novel insights from pathway analyses. 
 
Ingenuity pathway analysis (IPA) restricted to the 155 candidate causal genes confirmed that these 
are enriched for effects on the cardiovascular system and cell cycle functions (Online Table XVI). Pathway 
insights provided by the DEPICT framework identified 1,525 reconstituted genes sets that could be captured 
in 156 meta gene sets (Online Table XVII). The 4 most significant meta-sets were “complete embryonic 
lethality during organogenesis”, “blood vessel development”, “Anemia” and “SRC PPI subnetwork”. The 
“platelet alpha granule lumen”, “SRC PPI subnetwork”, “blood vessel development” and “hemostasis” had 
the largest betweenness centrality, an indicator of a node’s centrality in the network. The tissue enrichment 
analyses by DEPICT indicated blood vessels as the most relevant tissue (P= 4×10-7), 41 additional tissues 
or cell types were significantly enriched at FDR<0.05 (Online Table XVIII). We compared the contribution 
of novel information to previous work. The previous CardiogramPlusC4D analysis led to 457 reconstituted 
gene-sets (at FDR<0.05), the addition of the intermediate dataset UK Biobank of 150k individuals identified 
a total of 889 significant gene sets, substantially less than the current 1,525 gene sets (Figure 1; Online 
Table XVII). Considering all 10,968 possible gene sets, this study represents an increase from 4.16% to 
13.90% of all gene sets involved in CAD since the 1000 Genomes analysis of CardiogramPlusC4D in 2015. 
Genes implicated by DEPICT on the FDR<0.05 level are 94 in the previous data which has increased to 
540 genes. 
 
Insights in loci by associations with other phenotypes. 
 
To increase our understanding of potentially mediating mechanisms at the genetic variant level we 
searched the GWAS-catalog for previously reported variants. Of the 64 novel loci, 23 loci were in LD 
(r2>0.6) with genetic variants previously reported to be associated with other traits surpassing the genome 
wide significant (P<5×10-8) threshold (Online Table XIX). We found associations with anthropometric 
measurements (rs6905288, rs1591805, rs3936511, rs840616), anti-neutrophil antibody associated 
vasculitis (rs112635299), angiotensinogen measurements (rs699), coffee consumption (rs13723), C-
reactive protein (rs667920), pulmonary function (rs61848342, rs13723, rs112635299), fibrinogen levels 
(rs67920, rs16844401, rs2074158), glomerular filtration rate (rs12500824), HDL cholesterol (rs667920, 
rs10512861, rs6905288), LDL cholesterol (rs10512861), total cholesterol (rs6997340), triglycerides 
(rs667920, rs3936511, rs6905288, rs6997340), diabetes (rs1591805, rs3936511), blood pressure indices 
(rs260020, rs17080091, rs61776719, rs7696431, rs1317507), transferrin levels (rs6997340), QRS 
amplitude (rs13723), abdominal aortic aneurysm (rs885150, rs3827066), adiponectin measurements 
(Rs6905288), and age at menarche (rs1591805); full details can be found in Online Table XIX. We also 
explored the association of the 64 lead SNPs with a range of traits in UKbiobank Resource. Consistent with 
the GWAS-catalog search and in keeping with earlier observations in established CAD loci, several of our 
novel loci were associated with hyperlipidemia, blood pressure traits, diabetes and anthropometric traits 
(Figure 2). For example, rs6905288 (VEGFA) was also associated with waist-to-hip ratio and 
hyperlipidemia and rs61776719 (FHL3, UTP11L) was also closely associated with pulse pressure in UK 
biobank. Interestingly, we observed that 15 of 64 loci were associated with platelet counts. 
 
Genetic risk for CAD and association with CAD risk factors and outcome. 
  
To explore potential clinical relevance, we constructed a genetic risk score (GRS), weighted for 
their effects in CardiogramPlusC4D by multiplying the effect sizes with the number of effect variants of 
each variant in each individual and divided this GRS into quintiles. The associations with many different 
traits and diseases from the UK Biobank are visualized in Figure 2. The risk of a future diagnosis of atrial 
fibrillation and heart failure in UK Biobank participants was higher in quantile 5 individuals as compared 
to quantile 1 (HR 1.18 [95CI 1.10-1.27, P=1.2x10-6] and HR 1.59 [95%CI 1.43-1.77, P=3.3x10-18], 
respectively - Online Figure IV). In addition, all-cause mortality and especially cardiovascular mortality 
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was higher in individuals of quantile 5 compared to quantile 1 (HR 1.12 [95%CI 1.06-1.19, P=4x10-4] and 
HR 1.94 [95%CI 1.70-2.21, P=2x10-23], respectively - Online Figure IV).  
 
Role of regulatory DNA and fine-mapping of candidate causal variants. 
 
Across the genome, virtually all tissues showed significant enrichment of DNase I hypersensitivity 
sites providing limited indications for involved biology (Figure 3a and b). Minimal differential enrichment 
of functional elements for the identified genetic loci was observed in blood vessels and liver. To facilitate 
future functional studies directed at causal variants and molecular mechanisms, we prioritized variants via 
the probabilistic framework of Probabilistic Annotation INTegratOR (PAINTOR). As no clear differential 
enrichment was observed for tissue specific functional elements, we focused on DNA annotations from the 
study of Finucane et al17 that are not specific for tissue or cell types. PAINTOR determined the significance 
of each annotation to be causal (Figure 3c and d) and a model was constructed using LD information, P-
value distribution, and information on coding variation, conservation and H3K4me1 sites to prioritize 
potential causal SNPs of all 161 (known and novel) loci. This analysis yielded 28 variants at or above the 
95% confidence level for which we prioritized candidate genes (Online Table XX, Table 2).  
 
 





















P Annotation Candidate gene/mechanism
1p32.3 rs11591147 4 0.02 1.9x10-22 1.00 missense (T) PCSK9* 
1p13.3 rs602633 67 0.21 3.6x10-58 1.00 downstream SORT1$(130)^(51.1),SARS$(11.6),PSRC1(152),CELSR2$(108), ATXN7L2$(11.7) 
1q32.1 rs6700559 83 0.49 1.8x10-08 0.97 intronic CAMSAP2$(9.5)^(23.9), DDX59$(42.0)
2p24.1 rs16986953 66 0.07 1.1x10-16 1.00 intergenic -
2q35 rs2571445 50 0.40 1.6x10-12 0.97 missense (T) TNS1*$(121.5),DIRC3$(7.9) 
3p21.31 rs7633770† 49 0.44 1.1x10-08 0.97 intergenic ALS2CL$(8.6),RTP3^(49.6),LTF^(49.6)
3q26.31 rs12897† 67 0.41 1.2x10-09 1.00 UTR3 FNDC3B&$(8.8) 
4q21.22 rs11099493† 54 0.37 2.5x10-10 1.00 intergenic -
5q31.3 rs246600 15 0.50 6.5x10-17 1.00 intronic HMHB1^(159.2)
6p24.1 rs9349379 268 0.41 2.7x10-76 1.00 intronic EDN1$(2,2)^(23.9),TBC1D7$(15.9),PHACTR1$(55.7),GFOD1$(8.1)
7p21.1 rs2107595 71 0.18 1.3x10-24 1.00 intergenic TWIST1$(36.8)
7p13 rs2107732† 11 0.10 3.6x10-08 0.98 missense (T) CCM2*^(9.6),MYO1G^(22.9) 
7q32.2 rs11556924 95 0.38 1.4x10-23 1.00 missense (D) ZC3HC1*,NRF1^(38),KLF14^(216.9)
7q36.1 rs3918226 25 0.09 1.4x10-20 1.00 intronic NOS3$(6.0)
9p21.3 rs4977574 161 0.49 8.8x10-223 1.00 intronic CDKN2B$(4.7),^(133), MTAP^(168)
11p15.4 rs11601507† 3 0.06 5.6x10-13 1.00 missense (D) TRIM5*,OR52N1^(45),TRIM6^(49),OR52B6^(49)
11q13.1 rs3741380 207 0.48 2.8x10-11 0.95 missense (T) EHBP1L1*$(51.5) 
11q13.5 rs590121 122 0.28 1.5x10-10 0.98 intronic SERPINH1$(5.5),KLHL35^(23.7)
11q22.3 rs974819 428 0.24 1.1x10-28 0.99 intergenic PDGFD$(20.6),^(87.0) 
13q34 rs11617955 19 0.11 6.9x10-18 1.00 intronic -
13q34 rs1317507† 94 0.25 8.2x10-12 1.00 intronic PCID2^(22.5), CUL4A^(22.5) 
15q25.1 rs7173743 367 0.46 5.5x10-36 0.96 intergenic RASGRF1$(4.2),ADAMTS7$(33.3)
16q23.3 rs7500448 257 0.22 1.6x10-16 1.00 intronic CDH13$(70.2)^(64.8) 
17q21.32 rs17608766 178 0.17 8.2x10-10 1.00 UTR3 GOSR2&
19p13.2 rs116843064 7 0.03 3.6x10-10 1.00 missense (D) ANGPTL4* 
19q13.32 rs7412 39 0.07 2.1x10-35 1.00 missense (D) APOE*,APOC2^(64.1),CLPTM1^(64.1),APOC4^(64.1)
20q11.22 rs867186 >500 0.10 6.8x10-12 0.97 missense (T) PROCR*$(20.3),TRPC4AP$(42.9)^(116),GGT7$(4.6),EDEM2$(7.9),NCOA6^(75.1),HMGB3P1
^(75.1)
21q22.11 rs28451064 104 0.13 2.6x10-33 1.00 intergenic MRPS6$(17.4)^(238.6), SLC5A3$(32.1)^(238.6) 
*= Gene with a missense causal variant; ^=chromatin-interaction between the causal variant and the promotor of the gene; &=Gene of which the 
three prime untranslated region overlaps with the causal variant; $=eQTL gene; ()=the number between brackets indicates the significance –log(P), 
of the eQTL or chromatin interaction. †=SNPs of novel loci. D=deleterious (SIFT), T=Tolerated(SIFT). The column ‘#SNPs in locus’ corresponds 
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to the number of SNPs with a P<0.01 that are in low LD (r2>0.1) with the sentinel SNP. Genes in bold indicates converging evidence of a potential 
functional SNP-gene mechanism, further described in the methods. Online Table XX contains full details of the loci on the variant level. 
 
For example, rs974819 was prioritized as causal variant and could be linked to PDGFD by hi-C evidence and eQTL data in relevant tissues (Online 
Figure V). In total 15 of the 28 fine-mapped loci could be pinpointed to one single potential causal mechanism implicating a single variant. For two 
loci, there were 2 potential causal mechanisms (TRPC4AP/PROCR and MRPS6/SLC5A3) with equal evidence. 




The present study is the largest genetic association study of CAD performed to date. We report on 
the primary results and downstream bioinformatic analyses of the meta-analysis of de novo GWAS data 
derived from the UK Biobank combined with existing data from CARDIoGRAMplusC4D, leading to the 
inclusion of up to 122,733 cases and 424,528 controls. This study contributes to the existing literature by 
reporting 64 novel genetic loci representing 38% of all 161 GWAS identified CAD loci to date18. For the 
novel loci, a detailed catalogue of 155 candidate genes (based on proximity, gene-expression data, coding 
variation and physical chromatin interaction) is provided. We demonstrate that the increase in significantly 
associated CAD loci results in a large expansion of implicated reconstituted gene-networks, from 4% to 
almost 14%. Finally, by integrating genetic association strength, LD and functional annotation data, we 
performed fine-mapping of all 161 CAD loci, providing a novel credible list of causal variants and plausible 
genes to be prioritized for functional validation. 
 
The 64 novel genetic loci reported in this single manuscript is exceptionally large compared to 
previous manuscripts, including those of CARDIoGRAMplusC4D and others reporting on 10-15 novel loci 
each2–10. 34 of the 64 loci are significant in a robust reciprocal replication strategy between 
CARDIoGRAMplusC4D and the UK Biobank but another 30 are genome-wide significant in the overall 
meta-analysis as is commonly considered sufficient evidence7,10. The obvious reason for the large number 
of novel loci is the considerable number of novel CAD cases and non-CAD controls compared to these 
earlier efforts combined with less heterogeneity in samples, collection and definitions used. By increasing 
the sample size, more loci can be identified, more genes can be implicated and more gene-networks or 
pathways can be constructed. Not only is the increase of associated loci in the past decade rapidly outpacing 
functional validation, even understanding biological networks appears to insufficiently accommodate the 
increased amount of GWAS hits under the conceptual “polygenetic model”. This can be illustrated by the 
large increase of reconstituted gene-networks observed in our study. For the first time, we show that almost 
14% of all existing gene-networks are involved in the complex CAD trait (Figure 1), and this will only 
increase when further samples are added to the GWAS study making it increasingly more difficult to 
consider these all to be “key pathways”. In our data, we also observed genetic associations signals to be 
spread across most of the genome, and many of the novel 155 candidate genes do not have an obvious 
connection to CAD. In addition, virtually all cell types showed significant enrichment of DNase I 
hypersensitivity and other functional elements. These notions are all supportive of the “omnigenic model” 
which has recently been proposed by the Pritchard’s team suggesting that prevailing conceptual models for 
complex diseases are incomplete. The Omnigenic model hypothesizes that all gene regulatory networks are 
sufficiently interconnected such that all genes expressed in disease-relevant cells can influence the function 
of core disease-related genes and a major proportion of heritability can be explained by effects of genes 
outside key pathways19. To further our knowledge, it is questionable whether further increasing the GWAS 
sample size will resolve the outstanding issues concerning our incomplete understanding of cellular 
regulatory networks and our ability to differentiate core genes from peripheral genes. If the omnigenic 
model is indeed correct, detailed mapping of cell-specific regulatory networks will be essential to 
understand CAD. 
 
To facilitate functional research based on our findings, we not only provided extensive 
bioinformatic analyses of coding variation, gene-expression and chromatin interactions for the 64 novel 
loci, we also performed novel fine-mapping and presented statistically convincing arguments for causal 
genetic variants at 28 loci, linking 19 genes in the 161 CAD loci. In the known loci, these genes included 
APOE, PCSK9, ANGPTL4, and SORT1, all implicated as core-genes in lipid-metabolism. Recently, PCSK9 
has been validated in clinical trials20, and functional studies are also supporting a key role for SORT121. 
More recently, EDN1 has indeed been identified as the likely causal gene in the pathogenesis of CAD 
instead of the nearby PHACTR22. In the novel loci, we found evidence for causal variants linked to FNDC3B 








 DOI: 10.1161/CIRCRESAHA.117.312086   13 
(Fibronectin Type III Domain Containing 3B), CCM2 (CCM2 Scaffolding Protein), and TRIM5 (Tripartite 
Motif Containing 5). Indeed, the functional link between these genes and CAD is not obvious and remains 
to be determined. FNDC3B has been suggested to function as a positive regulator of adipogenesis.23 CCM2 
has been implicated in abnormal vascular morphogenesis in the brain, leading to cerebral cavernous 
malformations24 but is also expressed in the heart. Although its effect in the coronary arteries has not been 
investigated but Ccm2 knockdown in the mouse brain endothelial cells leads to increased monolayer 
permeability, decreased tubule formation, and reduced cell migration following wound healing25. TRIM5 
has been suggested to promote innate immune signaling and its activity is amplified by retroviral 
infections26. All SNP-gene mechanisms proposed in this manuscript should be experimentally sought out. 
Also, the analyses were restricted to variants available in the HRC imputation panel. Although this is the 
largest imputation panel to date it is only comprised of SNPs; future fine-mapping efforts are necessary that 
include non-SNPs as well, such as indels, to cover the additional aspects of the human variation landscape. 
However, a 95% credible set that contains just 1 potential causal variant per locus provides a first starting 
point for generating new hypotheses and scientific explorations.  
 
In our current work, we validated our previous finding that these genetic variants of CAD also 
predict the risk of atrial fibrillation, heart failure8 and extended it to all cause death. We also aimed to 
differentiate between stable CAD and acute myocardial infarction by performing multinomial logistic 
regression analyses. Most loci were not driven by one clinical presentation specifically. However, for two 
previously identified loci (rs9349379 (EDN1) and rs10947789 (KCNK5)) we found statistical evidence that 
these loci may be driven by acute myocardial infarction and not stable CAD. Also for this observation, 
functional hypotheses are to be developed and tested. Our variants might be driven mainly by non-fatal 
CAD and different variants might exist for fatal heart disease.  
 
  Some limitations of the current work are to be acknowledged. This work is based on statistical 
evidence and does not provide functional experimental validation. The genetic variants identified and the 
genes prioritized require further direct investigations in future studies to elucidate their role, and function, 
in the development and progression of CAD. However, in the short term, these data open up new 
possibilities to improve quantitative measures of genetic risk prediction. Recent data suggests that instead 
of operating in a deterministic fashion, high genetic risk is indeed modifiable by lifestyle27, 
pharmacotherapy28, and also by incorporation of genetic risk into shared decision making sessions with 
patients29.  
 
 In conclusion, our GWAS, meta-analyses, and bioinformatic analyses provide several novel 
insights into the biology of CAD. We report 64 novel loci, link 155 candidate genes and performed fine-
mapping of all old and novel loci, providing a credible list of causal genetic variants. However, with the 
ever-increasing sample size, our work is the first to indicate that an omnigenic model may be more 
appropriate to accommodate the complex genetic architecture of CAD, compared to a polygenic model. In 
addition to an expanded view, it also suggests new methods and tools are required to further our 
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FIGURE LEGENDS 
 
Figure 1. Network analyses of reconstituted gene sets. The total number of significant gene sets involved 
in CAD increased to 13.90% since the 1000 genome GWAS of CardiogramPlusC4D, considering all 
possible gene sets. Clustering by modularity using Gephi software indicated that pathways specific for 
cardiovascular/heart development, inflammation, lipids, kidney and coagulation clustered together. ‘PPI 
networks & Others’ indicates a remaining bin predominantly populated by Protein-protein interaction 
networks.  
 
Figure 2. Heatmap of associations in UK Biobank with novel loci. Heatmap of z-scores for different 
diseases and phenotypes in UK Biobank, aligned to increased risk of CAD. Only significant associations 
(FDR<0.01) are shown. The genetic risk score constructed with the known and novel loci, weighted using 
coefficients of CardiogramPlusC4D, is highlighted by the red rectangle.  
 
Figure 3. The role of regulatory DNA underlying CAD associated SNPs. Enrichment of genome-wide 
association analysis p-values in DNaseI hypersensitive sites (DHS). CAD SNPs at different GWAS 
threshold were significantly enriched in DHS footprints (a) and hotspots (b) across many different tissues 
and cell types. The fold enrichment was highly significant for most tissues and cell types (P<1×10-8) as 
indicated by the 4 colored circles next to the labels, 3 colored circles indicates P<1×10-7. Label sizes of 
tissue types were down sized due to space limitations; tissues-types may be represented by multiple 
samples, indicated by hash marks of the same color. (c) Subsequent prioritization of potential causal 
annotations underlying the 161 CAD loci also suggested that regions of DHS may be underlying the 
associations, but coding variants, conservation, 5-prime UTR and H3K4me1 annotations were more likely 
to be causal. (d) Posterior probabilities for causality for each variant in the 164 CAD loci were calculated 
by an empirical Bayes approach implemented in the Probabilistic Annotation INtegraTOR Framework 
(PAINTOR), taking into account LD, association statistics and the potentially causal annotations, and 
summarized in Table 2 and Online Table XX.  
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NOVELTY AND SIGNIFICANCE  
 
What Is Known? 
 
 Coronary Artery Disease (CAD) is a multifactorial disease with a substantial heritable 
component.  
 
 Genome wide association studies (GWAS) in the past decade have identified 96 loci associated 
with CAD and are believed to provide biological insights into “key pathways” under the 
presumption of a “polygenetic” model. 
 
What New Information Does This Article Contribute? 
 
 We have identified 64 additional loci, which were associated with CAD. We fine-mapped all 
new and known loci to provide evidence in support of the causal role of the genetic variants or 
genes in CAD. 
 
 Network analyses suggest a complex genetic architecture of CAD, which might not be fully 
captured by the prevailing “polygenetic” model of CAD.  
 
 This work lends supports to the “omnigenetic” model, proposing that associated genetic 
variants might not necessarily lay in key disease pathways. Instead, all gene regulatory 
networks maybe sufficiently interrelated such that all genes expressed, including those outside 
key disease pathways, may influence key disease related genes. 
 
CAD, a leading cause of death, is a complex multifactorial disease. GWAS of CAD have offered new 
biological insights and added to risk prediction and identification of drugable targets. We performed a large 
systematic meta-analysis of GWAS, involving 122,733 cases and 424,528 controls and identified 64 new 
genetic loci that were associated with CAD. Fine-mapping of all known and novel CAD loci highlighted 
potential causal SNP-gene mechanisms. A large proportion of all biological pathways and a plethora of 
human tissues were found to be associated with CAD for no obvious reason. This finding could indicate 
that the “polygenic” model may not uphold with ever increasing sample sizes for CAD genetics and the 
“omnigenic” model may be more appropriate to accommodate the increasing complexity. This study 
underscores the importance of tissue-specific dedicated mechanistic studies. New methods and tools are 
required to advance our understanding of genetic mechanisms influencing the development and progression 
of CAD. 
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Online Material & Methods 
UK Biobank individuals 
Participants were recruited with an age range of 40-69 years of age that registered with a general 
practitioner of the UK National Health Service (NHS). Between 2006–2010, in total 503,325 
individuals were included. All study participants provided informed consent and the study was 
approved by the North West Multi-centre Research Ethics Committee. Detailed methods used by UK 
Biobank have been described elsewhere. 
Ascertainment of coronary artery disease (CAD) 
Prevalence and incidence data on CAD was obtained at the Assessment Centre in-patient Health 
Episode Statistics (HES) and at any of the visits as described previously1. The prevalence and 
incidence of coronary artery disease conditions and events were captured by data collected at the 
Assessment Centre in-patient Health Episode Statistics (HES) download on September 10, 2016. CAD 
was defined using the following ICD 10 codes: I21-I25 covering ischemic heart diseases and the 
following Office of Population Censuses and Surveys Classification of Interventions and Procedures, 
version 4 (OPCS-4) codes: K40-K46, K49, K50 and K75 which includes replacement, transluminal 
balloon angioplasty, and other therapeutic transluminal operations on coronary artery and 
percutaneous transluminal balloon angioplasty and insertion of stent into coronary artery. Self 
reported CAD was also used in the definition (heart attack/myocardial infarction, coronary 
angioplasty +/- stent,  cabg and triple heart bypass). 
Non-CAD individuals defined the control population but to reduce biological misclassification and to 
improve power we excluded individuals from the control population if their mother, father or sibling 
was reported to suffer from ‘heart disease’. This approach has been validated previously1 and lead 
to the inclusion of 34,541 CAD cases and 261,984 non-CAD controls of the UK Biobank.  
The exact phenotype definitions of UK Biobank used in the baseline table and phenome scan are 
described in detail elsewhere1.  
Genotyping and imputation 
The Wellcome Trust Centre for Human Genetics performed quality control before imputation and 
imputed to HRC v1.1 panel. Analyses have been restricted to variants that are in the HRC v1.1. 
reference panel because UK10K imputation was unreliable at time of analyses. Quality control of 
samples and variants, and imputation was performed by the Wellcome Trust Centre for Human 
Genetics, as described in more detail elsewhere2. Sample outliers based on heterozygosity and 
missingness were excluded by the Welcome Trust Centre for Human Genetics, 373 additional 
participants were excluded based on gender discrepancies between the reported and inferred 
gender (using X-chromosome heterozygosity). 
Genetic analyses 
All genetic analyses in UK Biobank that are reported in this manuscript were adjusted for age, 
gender, the first 30 principal components (PCAs) to account for population stratification and 
genotyping array (Affymetrix UK Biobank Axiom® array or Affymetrix UK BiLEVE Axiom array). 
Genome wide association analysis in UK Biobank was performed using BOLT-LMM v2.3beta2, 
employing a mixed linear model that corrects for population structure and cryptic relatedness in a 
time efficient manner3. For the mixed model, we used directly genotyped variants that passed 
quality control, which were extracted from the imputed dataset, to ensure 100% call rate, and 
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pruned on linkage disequilibrium (first r2 < 0.05 and a second round of r2<0.045) to obtain roughly 
400k variants across the genome, as recommended by BOLT. The GWAS in UK Biobank was 
performed on a confined set of 7,947,838 SNPs that were common in UK Biobank and available in 
the CARDIoGRAMplusC4D 1000Genomes4, Metabochip5,6 and/or exome-chip7 studies ( downloaded 
from http://www.cardiogramplusc4d.org/ downloads and 
http://www.phenoscanner.medschl.cam.ac.uk ). The genomic control, lambda was 1.25 but the 
intercept (1.0287(se=0.0093)) of the LDscore regression suggested no inflation due to non-polygenic 
signals (Online Figure VI), the residual inflation of 2.8% is most likely due to the sample/reference LD 
Score mismatch between UKBiobank and 1000 Genomes8.  
The Beta estimates of the top-SNPs in UK Biobank were re-estimated using a logistic regression with 
sandwich robust standard errors that were clustered by family to account for relatedness among UK 
Biobank participants, which were used in the meta-analyses9. Families were inferred from the 
kinship matrix, clustering all 3rd degree relatives or higher together (kinship coëfficiënt > 0.0442).  
The GWAS dataset of CARDIoGRAMplusC4D’s 1000Genomes4 was complemented with the 
1000Genomes4+Metabochip study5,6, which was used for the discovery of SNPs associated with CAD 
P<0.0001 and used to replicate independent signals found in the UK Biobank GWAS.   
To obtain a set of independent SNPs, SNPs P<0.0001 were clumped together based on LD r2>0.1 and 
5,000kb distance, using plink’s clumping procedure. A locus was defined as a 1MB region at either 
side of the highest associated SNP in a locus.   
We used a reciprocal two-stage sequential discovery and replication design with independent SNPs 
that were suggestive for their association with CAD (P<0.0001). First, we determined independent 
SNPs (P<0.0001) in UK Biobank and used the exome-chip7 or 1000Genomes4+Metabochip study5,6 for 
replication, second we determined independent SNPs in the exome-chip7 or 
1000Genomes4+Metabochip study6 and used UK Biobank as replication. To account for multiple 
testing in the replication phase we applied P<0.05 after Bonferroni adjustment for the number of 
tests (649 tests in stage 1, 568 tests in stage 2), considering the direction of effect in the discovery 
phase (1-sided). To minimize false positive findings, a SNP was only considered to be true if 
significant if both replicated and surpassing the genome-wide significance threshold (P<5x10-8) in 
the inverse-variance meta-analysis. Finally, we performed a meta-analysis of the GWAS of UK 
Biobank and the 1000Genomes4+ study6, which was used to plot the regional associations of the 
novel loci and Manhattan. Over-dispersion of association statistics in the 
1000Genomes4+Metabochip study5,6  was adjusted using genomic control by the consortium; in UK 
Biobank we adjusted the over-dispersion by the LDscore’s intercept 1.0287.  
The additive model was compared to a dominant and recessive model for genome wide significant 
SNPs using SNPTEST v2. Since SNPTEST does not account for relatedness, the analysis was restricted 
to independent individuals (more details under “Details on regression analyses and accounting for 
relatedness”), explaining why some SNP-associations are less significant compared to the discovery 
analysis.  
Heritability 
SNP-heritability was estimated in the UK Biobank using BOLT-REML, results were transformed from 
the observed to the liability scale using linear transformation. The proportion of variance explained 
by the identified variants was calculated by taking the difference between the total-SNP heritability 
and the SNP-heritability after including the identified SNPs in the model as covariates. BOLT-REML 
estimated the pseudo (SNP) heritability at 0.104 (0.001), which is 27.8% on the liability scale, slightly 
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higher than the previous estimate1; 15.1% of the SNP-heritability could be explained by the 161 
SNPs, 4.1% by the 64 novel SNPs.  
Assessment of potential bias due to overlapping samples 
The exome-chip7 or 1000Genomes4+Metabochip study6  recruited individuals living in the UK (see 
table below) that might also have been invited to participate in the UK Biobank cohort.  
We estimated the influence of potential duplicate samples on test statistics. The CARDIoGRAM 
cohorts are heterogeneous for their age-ranges, inclusion-dates, and often of mixed-ancestry 
reducing the risk of duplicates, as the age range of recruitment for the UK Biobank was 40-69yrs (in 
2006-2010).  
Table CARDIOGRAM+C4D cohorts that may contain UK individuals overlapping with UK Biobank.  
Cohort PMID % recruited 
in UK 










EPIC CAD 7 10466767 100 50 8423 4212 
GoDARTS CAD 7 16710446 100 100 4340 4340 
PROCARDIS7 16710446 61.61 100 4710 2902 
EPIC- CVD 6 17295097 5.85 71 18642 1091 
GODARTS4 9329309 100 100 3064 3064 
LOLIPOP4 18454146 100 100 6548 6548 
WTCCC4 17554300 100 100 4864 4864 
HPS4 12114036 100 24 5458 1305 
CARDIOGENICS4 22144904 67.5 100 802 541 
ITH_24 16271645 0.02 100 850 0 
PROSPER4 12097148 43.42 0 5244 0 
PROCARDIS4 16710446 61.61 70 12264 5289 
    Total meta-
gwas 22702 
 
    total exome 11454 
 
The 503,325 participants of UK Biobank represents a 5.5% response rate10, of the approximately 
9.150.000 invited individuals. Considering around 23.800.000 UK inhabitants within the age-range 
(40-69 years) and 22,702 Cardiogram UK participants, the chance for random sample overlap 
selection is 0.021, which equals 480 individuals; or less than 0.1% of this study’s sample size, at 
most. 
The influence of 0.01% duplicated sample on test-statistics is negligible (Online Figure VII). To 
estimate the effect of overlapping samples, a random set of 1000 case/control samples and SNPs 
associated at P=1x10-8 was simulated; then a random overlap of X% samples was introduced for 5000 
times and the mean –log(P-value) and 95% confidence interval of the SNP-CAD associations was 
determined. This process was repeated for 0.1 to 100% sample overlap.  
Separately, we estimated the influence of potential sample overlap between UK Biobank and 
1000Genomes4+Metabochip study6 using mtag ("Multi-Trait Analysis of GWAS" , 
https://github.com/omeed-maghzian/mtag). Mtag (with the options ‘--equal_h2 --perfect_gencov’) 
performs a meta-analysis taking into potential sample overlap using estimates of LD Score regression 
and modeling it snp-by-snp. The LD score regression intercept of the genetic covariance was 
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estimated at 0.022 (0.008), which could suggest that there may be some degree of sample overlap, 
but meta-analysis results by mtag are virtually unchanged (Online Table VI). 
Genetic risk score  
A weighted genetic risk score was constructed using effect estimates of the CARDIoGRAMplusC4D 
data as previously described1 using the 97 previously identified variants and the 64 novel ones. For 
this, the number of CAD increasing risk alleles were summed after multiplying the alleles with the 
corresponding β (based on the CARDIoGRAMplusC4D 1000Genomes4+Metabochip study5,6) to avoid 
any potential reverse causation and standardized to a mean of zero and a standard deviation of 1.  
eQTL and meQTL analyses 
To search for evidence of functional effects of SNPs at CAD loci multiple eQTL databases were 
examined; GTEX version 611,  Stockholm-Tartu Atherosclerosis Reverse Network Engineering Task  
(STARNET)12, cis-eQTL datasets of Blood13–15 and cis-meQTLs16. Only eQTLS/meQTLs that achieved 
P<1x10−6 and were in LD (r2>0.8) with the queried GWAS variant were considered significant.  
Several eQTLs were observed in different tissues/studies, adding to the evidence of being a true 
eQTL.  
Identification of Candidate Genes 
We prioritized candidate genes in each of the 64 loci based on the following criteria: (1) The nearest 
gene or any gene located within 10 kb of the sentinel genetic variant, (2) Any gene containing 
protein coding variants in linkage disequilibrium (r2 > 0.8, UK Biobank) with the sentinel genetic 
variant. (3) Expression QTL (eQTL) analyses in cis; we search for eQTLs (sentinel genetic variants or 
genetic variants in linkage disequilibrium, r2 > 0.8, UK Biobank) see above. We only considered eQTLs 
for which the top-eQTL was in linkage disequilibrium (r 2 > 0.8, UK Biobank) with the sentinel genetic 
variant and for which the eQTL P<1x10−6. (4) DEPICT-genes (see section below for more details). (5) 
Long range chromatin interaction genes, Hi-C data was queried using 
http://yunliweb.its.unc.edu/HUGIn for the variant location using the ‘Association’ tab. A gene was 
considered significant if the interaction between the variant’s location and promoter of a gene was 
significant by -log(P)<20.  
Fine-mapping for causal variants and regulatory elements  
To obtain insights into cell type specific functional annotations and enrichment we applied the 
nonparametric GARFIELD17 approach on the genome-wide summary statistics of the complete meta-
complete using default settings. Candidate causal variant were identified by the probabilistic 
framework of Probabilistic Annotation INTegratOR (PAINTOR) incorporating LD information, the P-
value distribution of significance across GWAS loci and genetic annotations18. As input we used the 
64 newly identified leadSNPs and 97 previously identified variants (the highest associated variant 
was selected in CardiogramPlusC4D 1000 genomes analysis), all SNPs in LD of r2>0.1 and a P-value 
<0.01 in the complete meta-analysis of UKBiobank and CardiogramPlusC4D was considered as a 
locus. Because GARFIELD and DEPICT indicated that many different types of tissues and cell types 
may be underlying the CAD loci, and the number of annotations in complete PAINTOR model is 
limited to 3-5, we used genetic annotations that were not cell-type specific as described previously 
in Finucane et al19, and coding variants identified by dbNSFP20. PAINTOR determined the significance 
of each annotation (Figure 3c) after which we performed a forward selection process based on 
significance to select the most relevant genetic annotations for the loci. The model for prioritization 
included coding variants, conservation scores and H3K4me1 regions; any additional annotations did 
not increase the model-fit and/or were highly correlated with one of the annotations already in the 
model. Potential SNP-Gene mechanisms were highlighted by missense variants (highly enriched 
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among causal variants), utr-3 variants together with evidence of an eQTL of the same gene and 
significant long-range interactions of the SNP location with a gene’s promoter that is also a 
significant eQTL.  
In silico functional annotations of regulatory elements of the leads SNPs were performed with 
annotations described in Finucane et al19, but also cell-type specific chromatin state, protein binding 
annotation from the Roadmap Epigenomics21 and ENCODE22 projects, sequence conservation across 
mammals and the effect on regulatory motifs by the HaploReg tool (v4.1)23. 
Mouse Genome Informatics (MGI) analyses 
We systematically searched the international database resource for the laboratory mouse (MGI-
Mouse Genome Informatics) for all candidate genes and manually curated Mammalian Phenotypes 
(MP) identifiers related to the cardiovascular system and others potentially relevant to the 
pathogenesis of CAD. 
Data-driven Expression-Prioritized Integration for Complex (DEPICT) analyses 
DEPICT systematically identifies the most likely causal gene at a given associated locus, tests gene 
sets for enrichment in associated SNPs, and identifies tissues and cell types in which genes from 
associated loci are highly expressed (see Pers et al.24 for a detailed description of the method). 
DEPICT.v1.beta version rel194 for 1KG imputed GWAS (8.2G) obtained from 
https://data.broadinstitute.org/mpg/depict/ was used to perform an integrated gene function 
analyses. DEPICT was ran with default settings using all SNPs that achieved P<1x10-5 as input, as 
suggested24. For comparison with previous datasets DEPICT was applied to the CardiogramPlusC4D 
1000 genomes analysis4, and CardiogramPlusC4D + intermediate dataset of UK Biobank1, using the 
same settings.  Both nominal P-values and false discovery rates (FDRs) were calculated. Networks 
were visualized using Gephi software (www.gephi.org). 
Ingenuity Pathway Analysis (IPA) analyses 
Ingenuity Pathway Analysis® (IPA, Qiagen’s Ingenuity Systems, Redwood City, CA, USA; 
www.ingenuity.com) June 2017 release was used and focused on the potentially relevance of the 
novel 47 candidate genes. The default parameters set were: 1. The Ingenuity Knowledge Base was 
set as the reference set; 2. Both direct and indirect relationships were considered; and 3. Only 
relationships that were experimentally observed were considered. 4. Networks were generated with 
a maximum size of 35 genes.  
GWAS catalog analyses 
The GWAS catalog database was downloaded from https://www.ebi.ac.uk/gwas/ and queried by 
searching for SNPs in a 1MB region of the novel SNPs found in this study. Next, LD was determined 
by calculating the r2 and D’ in UK Biobank between the GWAS catalog SNPs and the SNPs of this 
study. 
Details on regression analyses, accounting for relatedness and phenome wide analysis 
All regression analyses (Linear, logistic or multinomial logistic) were carried out using STATA-SE 
between phenotypes and SNPs or the genetic risk score, and were performed with sandwich robust 
standard errors that were clustered on family to account for relatedness (unless stated otherwise). 
Families were inferred from the kinship matrix and based on 3th degree relatives or higher (kinship 
coëfficiënt > 0.0442). All analyses in this manuscript were adjusted for age, gender, the first 30 
principal components and genotyping array to account for population stratification. Multinomial 
logistic regression analyses in STATA (mlogit) were performed to assess the extent to which genome 
wide significant SNPs were or were not driven by myocardial infarction. A Wald test was performed 
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to determine significance in beta–estimates between CAD(non-myocardial infarction) vs controls 
and CAD (myocardial infaction) vs controls, by STATA-SE’s ‘test’ command.  
Cox regression analyses adjusted for age, gender, 30 principal components and the genotyping array 
were used to evaluate the predictive power of the genetic risk score on new onset disease and 
mortality. To account for relatedness in the Cox regression analyses we pruned families (>3th 
degree, kinship coefficient <0.0442) using an iterative approach to keep a maximum independent set 
of participants, based on the genotype missingness rate; as a result, 74,477 related individuals were 
removed for the cox regression analyses. For disease phenotypes, individuals were excluded when 
they were reported to have the particular disease at baseline or in history to study new onset 
disease only.  
We tested the association of the newly identified SNPs and the genetic risk score of CAD with a wide 
range of phenotypes using linear or logistic regression analysis in UK Biobank to create a heatmap of 
the Z-scores that are aligned with CAD increasing risk, for this only FDR<0.01 significant associations 
are depicted in colored squares (hierarchical clustered).  




External resources and bioinformatics tools 
 
Name Description URL  
BOLT-LMM/REML Tool for Genome wide 
association using mixed 
model approach 
https://data.broadinstitute.org/alkesgroup/BOLT-LMM/ 
PLINK 1.9/2.0 used to handle genetic 
data 
https://www.cog-genomics.org/plink2 
QCTOOL used to handle genetic 
data 
http://www.well.ox.ac.uk/~gav/qctool/#overview 
Bgenix used to handle genetic 
data 
https://bitbucket.org/gavinband/bgen/wiki/bgenix 
DEPICT Pathway analyses https://data.broadinstitute.org/mpg/depict 
HUGIN Analysis of Hi-C data http://yunliweb.its.unc.edu/HUGIn 
GWAS catalog Data based of gwas hits https://www.ebi.ac.uk/gwas/ 
PAINTOR Fine-mapping software https://github.com/gkichaev/PAINTOR_V3.0 
Annotations of 
figure 3    
- https://data.broadinstitute.org/alkesgroup/LDSCORE/ba
seline_bedfiles.tgz 





Haploreg Annotation of fine-
mapped variants 
http://archive.broadinstitute.org/mammals/haploreg 
Ingenuity IPA Pathway analysis www.ingenuity.com 
Cardiogram GWAS  http://www.cardiogramplusc4d.org; 
http://www.phenoscanner.medschl.cam.ac.uk 
UK Biobank  http://www.ukbiobank.ac.uk 
LD score LD score regression https://github.com/bulik/ldsc 
mtag Multi-Trait Analysis of 
GWAS 
https://github.com/omeed-maghzian/mtag 
ukpheno R package used to 
generate phenotypes of 
UK Biobank 
https://github.com/niekverw/ukpheno 
Locuszoom Generation of regional 
plots 
http://locuszoom.sph.umich.edu 
GTEx eQTL database http://GTExportal.org 
NESDA NTR  eQTL database https://eqtl.onderzoek.io 
Blood eQTL browser  eQTL database http://genenetwork.nl/bloodeqtlbrowser/ 





Online Figure Legends 
 
Online Figure I. Flow scheme of analysis strategy. 
Flow scheme of the analysis strategy. 2-stage reciprocal design was adopted, (A) stage 1 was UK 
Biobank as discovery cohort, and stage 2 data of the CARDIoGRAMplusC4D as replication identifying 
13 novel loci, (B) stage 1 was CARDIoGRAMplusC4D consortium as discovery and stage 2 UK Biobank 
as replication, identifying 21 additional novel loci. (C) Upon genome wide meta-analysis, 30 
additional new loci were identified (Table 1). 
 
Online Figure II. Manhattan plot 
Manhattan plot showing meta-analysis results for CAD under an additive model. P values are 
truncated at -log10 (P) = 40. Markers shown are from the meta-analysis of UK Biobank with 
CARDIoGRAMplusC4D (see also Online Table III-VI). The gray dashed line denotes the GWAS (P < 
5×10-8) significance threshold. Known CAD risk markers are shown in grey. The 64 novel CAD-
associated are represented by the red peaks (Table 1). 
 
Online Figure III. Regional association plots 
Regional plots of the 64-novel genome-wide associated loci with CAD.  LD (r2) was based on the UK 
Biobank cohort. P-values were based on the genome wide meta-analysis to provide an accurate 
overview of the P-value distribution among variants at each locus; this is also the reason that for 
some regional plots the highest associated SNP is not the highlighted variant that was taken for 
replication. 
 
Online Figure IV. Clinical outcome for GRS Quintiles 
 
Online Figure V. Example of Fine-Mapping result 
The location of the fine-mapped causal variant rs974819 can be functionally linked with the PDGFD  
gene via long-range interactions in aorta in Hi-C data (a) and the association of rs974819 with gene 
expression of PDGFD in aorta (b). The black vertical line in the middle of the Hi-C plot indicates the 
location of rs974819 (the ‘anchor’ position); the black horizontal line indicates observed interaction 
counts, the red horizontal line shows the expected interaction counts and the blue horizontal line 
indicates bonferonni significant interactions (threshold shown in purple dotted line). The yellow area 
indicates that the significant interaction is overlapping a promoter region of a candidate gene. The 
long-range interaction was especially significant in mesenchymal stem cells, which may be explained 
by the role of very similar platelet-derived growth factors such as PDGFD-AA and BB in mesenchymal 
stem cells proliferation and angiogenesis (c). The variant overlapped with an enhancer mark specific 
for mesenchymal cells (d).  
 
Online Figure VI. Quantile-Quantile (QQ) plot 
The Quantile-quantile (Q-Q) plot of the GWAS in UK Biobank. The intercept of LD score suggests no 
inflation due to non-polygenic causes. 
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Online Figure VII. Influence of potential sample overlap 
The influence of sample overlap was investigated by simulating random CAD observations and an 
associated SNP at a predefined P value (red horizontal line). Then the mean P value (y-axis) with the 
95% confidence interval was determined of the P value distribution that was created by randomly 
introducing a sample overlap of X% for 5000 times. This process was repeated for each X between 
0.1 and 100% sample overlap (x-axis, black dots). The predefined P value was set at P=1e-8. The SNP 
simulated had a minor allele frequency of 0.4, but results should be independent of this considering 
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